LONDON: Isomorphic Labs has closed a $2.1 billion Series B led by Thrive Capital, one of the largest private rounds ever for an AI drug discovery company. The financing, announced by the company on May 12, 2026, brings Isomorphic’s total capital raised to roughly $2.6 billion. New investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund joined existing backers Alphabet and GV, according to the company’s announcement.
The DeepMind spinout, founded in 2021 by CEO Sir Demis Hassabis and led day-to-day with President Max Jaderberg, said the capital will scale its IsoDDE drug design engine and push its internal drug candidates toward Phase 1 trials. Hassabis told reporters the company now expects its first clinical trials by the end of 2026, a delay from his earlier target of having AI-designed drugs in trials by the end of 2025.
Why Thrive Capital Is Backing an AI Drug Company
Thrive Capital, the firm founded by Josh Kushner, is best known for writing the biggest checks in consumer software and AI infrastructure. OpenAI, Stripe, and Ramp anchor its portfolio. Leading a $2.1 billion biotech round is a directional bet that AI-native drug discovery now belongs to the same investing playbook as foundation-model companies, not traditional pharma venture.
The thesis behind the round is straightforward. Traditional drug development takes 10 to 15 years per molecule and costs north of $2 billion before a single approval. Foundation models trained on biological data, the bet goes, can compress that timeline by replacing wet-lab guesswork with computational design. Isomorphic’s commercial validation already includes upfront payments and milestone deals worth more than $1.7 billion from Eli Lilly alone, plus an expanded Novartis collaboration and a January 2026 multi-target agreement with Johnson & Johnson.
The round also signals that sovereign capital is now active at the company level in the AI race. MGX, the UAE’s AI investment vehicle, and the UK Sovereign AI Fund participating tells you that nation-state AI strategy has moved beyond chips and data centers into backing specific frontier-AI firms. For an Alphabet-adjacent company headquartered in London, the UK fund’s participation also reads as industrial policy. The pattern echoes Amazon’s $100 billion Anthropic commitment and the broader trend of strategic capital concentrating in frontier-AI labs rather than diversifying across early-stage startups.
What does the Isomorphic Labs Series B mean for AI biotech founders?
The round gives AI-native biotech a template that did not exist before. Until now, AI drug-discovery startups have had to partner-and-license, letting pharma own the molecule in exchange for milestone payments. A $2.1 billion war chest lets Isomorphic carry its own candidates into the clinic without trading equity in the molecules. For founders raising AI biotech, the round is a proof point that infrastructure-style capital is available for companies that can show predictive performance.
Three signals matter for the broader market. Foundation-model capital is crossing into biology, which compresses the gap between AI-first biotechs and traditional pharma venture. Sovereign funds are picking winners at the company level, not the sector level. And Alphabet keeps double-counting its AI bets, with Isomorphic, Anthropic, and Waymo all sitting outside Google’s P&L but inside its strategic footprint, an arrangement that increasingly defines how the largest AI-adjacent platforms are financed. The same investor concentration is visible in DeepSeek’s $20 billion first outside round and the recent OpenAI deployment-company structure, where AI infrastructure now attracts capital in 10-figure increments rather than the 9-figure rounds that defined the prior cycle.
The implications for AI biotech operators are concrete. Hiring against a $2.6 billion balance sheet pulls senior chemistry and clinical talent toward Isomorphic in a market where wet-lab biology PhDs are already scarce. Smaller AI-first biotechs raising Series A and B rounds in 2026 should expect tougher recruiting and a more crowded ICML and NeurIPS hallway when it comes to recruiting ML-for-biology researchers.
The risk is unchanged from a year ago. Model performance on benchmarks has not yet translated into clinical wins for any AI-first biotech, and the capital intensity of running Phase 1 trials is now real for Isomorphic in a way it was not when the company existed purely as a discovery engine. The $2.6 billion total raised buys runway, not certainty.
What to Watch Next
The next inflection point is the first clinical trial. Isomorphic said it expects to enter the clinic by the end of 2026, which would put the company on a 12-to-18-month watch for an Investigational New Drug application and a Phase 1 readout. The therapeutic programs to track are in oncology and immunology, the two areas Isomorphic has flagged for its internal pipeline.
The second is partnership economics. The Eli Lilly deal’s $1.7 billion milestone ceiling and the J&J cross-modality program both have triggers tied to design output and preclinical progress. Disclosed milestone hits would mark the first commercial validation of an AI-designed molecule from this generation of platforms. According to Hassabis’s prior public statements and Bloomberg’s reporting on the round, the company has not disclosed which specific programs will reach the clinic first.
The third is what Thrive does next. A $2.1 billion biotech check is unusual for the firm, and either signals a one-off thesis bet on Isomorphic or the start of an AI-native biotech vertical inside the portfolio. Founders raising in adjacent categories should expect Thrive’s interest to extend, much like the firm’s recent Ramp $40 billion round signaled an appetite for late-stage software bets at scale. Protein design, generative chemistry, and AI-native clinical trial platforms are the most obvious adjacencies.
